Treatment of pediatric patients with Down syndrome, acute lymphoblastic leukemia, and hepatitis C infection by directacting antivirals
Gulhane Medical Journal, cilt.64, sa.2, ss.201-203, 2022 (Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 64 Sayı: 2
- Basım Tarihi: 2022
- Doi Numarası: 10.4274/gulhane.galenos.2021.02996
- Dergi Adı: Gulhane Medical Journal
- Derginin Tarandığı İndeksler: Scopus, Academic Search Premier, CAB Abstracts, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.201-203
- Anahtar Kelimeler: children, Direct-acting antiviral, Down syndrome, hepatitis C infection
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Millions of people worldwide suffer from hepatitis C, which can lead to hepatitis, cirrhosis, and hepatocellular carcinoma. The risk of hepatitis C virus (HCV) infection is increased in patients with leukemia due to the frequent need for blood transfusion. Owing to their proven effectiveness in treating HCV infection, direct-acting antivirals (DAAs) have become a new treatment approach in children older than 12 years. The patient present in this article is a 9-yearold boy who had acute lymphoblastic leukemia and Down syndrome, who was diagnosed with hepatitis C infection and was successfully treated with a combination of DAA glecaprevir (250 mg/day) and pibrentasvir (100 mg/day) over 8 weeks.